Expert opinion on investigational drugs最新文献

Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial.

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-20 DOI: 10.1080/13543784.2024.2443756

Xin Huang, Xiang Hong, Shuang Yang, Ling Ye, Xiaoyan Yang, Chang Cui, Qian Wu, Wei Wang, Jie Huang, Guoping Yang

{"title":"Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial.","authors":"Xin Huang, Xiang Hong, Shuang Yang, Ling Ye, Xiaoyan Yang, Chang Cui, Qian Wu, Wei Wang, Jie Huang, Guoping Yang","doi":"10.1080/13543784.2024.2443756","DOIUrl":"10.1080/13543784.2024.2443756","url":null,"abstract":"Background: GR1603 is a monoclonal antibody targeting the type I interferon receptor. The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of GR1603 in healthy volunteers.Methods: Healthy adults (≥18 years old) were enrolled in a placebo control, dose-escalation Phase I clinical trial receiving a single injectable dose of GR1603. Follow-up was 12 weeks. Adverse event (AE) profiles, vital signs, and blood samples were collected for assessment of safety, PK, and expression of type I interferon inducible genes.Results: Of the 46 subjects, 44 completed treatment. In the experimental group of 34 subjects (mean age 26.6 years), 30 experienced treatment-emergent adverse events (TEAEs), with a total of 102 occurrences, resulting in an incidence rate of 88.2%. The most commonly reported drug-related AEs were upper respiratory tract infection (17.6%), all of which were ≤ grade 2. GR1603 exhibits non-linear PK in the dose range of 0.1 mg/kg to 9 mg/kg. All samples were negative for anti-drug antibodies before and after dosing. The degrees of IFN gene signature were significantly inhibited in the higher dose groups.Conclusion: The safety/tolerability, PK and exploratory metrics observed in this study support further clinical development of GR1603.Clinical trial registration: www.chictr.org.cn/searchproj.html identifier is ChiCTR2100045628.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-7"},"PeriodicalIF":4.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-17 DOI: 10.1080/13543784.2024.2441865

Eda Kaya, Yusuf Yilmaz, Naim Alkhouri

{"title":"Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.","authors":"Eda Kaya, Yusuf Yilmaz, Naim Alkhouri","doi":"10.1080/13543784.2024.2441865","DOIUrl":"10.1080/13543784.2024.2441865","url":null,"abstract":"Introduction: Glucagon-like peptide-1 receptor (GLP-1 R) agonists have demonstrated remarkable effectiveness in the treatment of obesity and type 2 diabetes. Although these agents provide beneficial effects for metabolic dysfunction-associated steatohepatitis (MASH) through their glucose-lowering and weight-reducing properties, their efficacy in promoting fibrosis regression remains unproven. Survodutide, an investigational dual agonist that simultaneously targets both the glucagon receptor (GCGR) and GLP-1 R, has emerged as a promising therapeutic candidate for the comprehensive management of obesity and MASH. By engaging these two critical receptors, this drug has the potential to offer a broad spectrum of metabolic benefits, addressing multiple pathogenic mechanisms underlying these interrelated disorders.Areas covered: This review examines the pharmacological profile, clinical efficacy, and safety data of survodutide derived from phase 1 and 2 clinical trials.Expert opinion: Survodutide's dual agonism of the GCGR and GLP-1 R may surpass the efficacy of selective GLP-1 R agonists, demonstrating significant potential in resolving MASH and promoting fibrosis regression. The drug is generally well tolerated, with primarily manageable gastrointestinal adverse effects. As survodutide progresses through phase 3 clinical development, its potential to provide a more effective and holistic approach to treating MASH and its comorbidities may significantly improve patient outcomes and quality of life.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1167-1176"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Promising selective progesterone receptor modulators: what's new in female contraception? 前景看好的选择性孕酮受体调节剂：女性避孕的新动向？

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-18 DOI: 10.1080/13543784.2024.2422838

Anita Nelson, Marit Pearlman Shapiro

{"title":"Promising selective progesterone receptor modulators: what's new in female contraception?","authors":"Anita Nelson, Marit Pearlman Shapiro","doi":"10.1080/13543784.2024.2422838","DOIUrl":"10.1080/13543784.2024.2422838","url":null,"abstract":"Introduction: Selective progesterone receptor modulators (SPRMs), such as mifepristone and ulipristal acetate (UPA), have demonstrated high efficacy and safety as single-dose treatments for medication abortion and emergency contraception (EC). Other obstetrical and gynecologic applications have emerged, both for episodic and ongoing uses. The potential of these compounds to provide estrogen-free, ongoing contraception is promising; however, the rare, but serious, hepatic injury cases seen with UPA have put at least a temporary halt to further research in this area.Areas covered: This paper reviews the biophysical impacts and clinical applications of SPRMs in women's reproductive health, with a focus on the roles of mifepristone and UPA in family planning. Given the political environment, especially in the United States where these applications may be threatened, extensive description is dedicated to mechanisms of action of these agents.Expert opinion: Both mifepristone and ulipristal acetate are first-line options for single-use applications. There continues to be a need for estrogen-free ongoing contraception that does not have unpopular impacts on bleeding caused by contraceptive methods and for treatments for heavy menstrual bleeding. However, current restrictions on UPA limit longer term use. Perhaps other SPRMs without hepatic impacts may emerge to fill this need.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1187-1198"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic encephalopathy: experimental drugs in development and therapeutic potential. 肝性脑病：开发中的实验药物和治疗潜力。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1080/13543784.2024.2434053

Antonio Gil-Gómez, Rocío Muñoz-Hernández, Filomeno Martínez, Fernando Jiménez, Manuel Romero-Gómez

{"title":"Hepatic encephalopathy: experimental drugs in development and therapeutic potential.","authors":"Antonio Gil-Gómez, Rocío Muñoz-Hernández, Filomeno Martínez, Fernando Jiménez, Manuel Romero-Gómez","doi":"10.1080/13543784.2024.2434053","DOIUrl":"10.1080/13543784.2024.2434053","url":null,"abstract":"Introduction: Hepatic encephalopathy (HE) presents a complex pathophysiology, creating multiple potential treatment avenues. This review covers current and emerging treatments for HE.Areas covered: Standard therapies, including non-absorbable disaccharides and rifaximin, are widely used but show inconsistent efficacy. Alternatives such as polyethylene glycol and L-ornithine L-aspartate have been effective in certain cases. Advancements in understanding HE reveal a growing need for personalized treatments. Novel approaches targeting immune modulation and neuroinflammation are under investigation, though clinical translation is slow. Nutritional interventions and fecal microbiota transplantation show potential but lack robust evidence. Innovative therapies like gene and cell therapies, as well as extracellular vesicles from mesenchymal stem cells, present promising avenues for liver disease treatment, potentially benefiting HE.Expert opinion: A key challenge in HE research is the design of randomized clinical trials, which often suffer from small sample sizes, heterogeneity in patient population, and inconsistent blinding. Additionally, the multifactorial nature of HE, together with a high spontaneous response rate, complicates efforts to isolate treatment effects. Despite current limitations, ongoing research and technological advances hold promise for more effective and individualized HE treatments in the future.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1219-1230"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibroblast growth factor therapies in biliary tract cancers: current and future state.

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-04 DOI: 10.1080/13543784.2024.2430201

Teerada Siripoon, Conor O'Donnell, Zhaohui Jin, Amit Mahipal

{"title":"Fibroblast growth factor therapies in biliary tract cancers: current and future state.","authors":"Teerada Siripoon, Conor O'Donnell, Zhaohui Jin, Amit Mahipal","doi":"10.1080/13543784.2024.2430201","DOIUrl":"10.1080/13543784.2024.2430201","url":null,"abstract":"Introduction: Cholangiocarcinoma is the rare and aggressive tumor with poor prognosis and limited therapeutic options. Recently, there have been promising developments in molecular targeted therapies for patients following the progression of first-line chemotherapy and immunotherapy combinations. Dysregulation of fibroblast Growth Factor Receptor (FGFR) signaling is significantly associated with tumorigenesis of intrahepatic cholangiocarcinoma and has been identified as a targetable alteration. This was possible through the discovery of crucial insights into the biochemical mechanisms and pathophysiology of the FGFR pathway.Areas covered: This review summarizes the current state of FGFR targeted therapies, mechanisms of resistance, and future directions for FGFR-targeted therapies in patients with cholangiocarcinoma.Expert opinion: Currently, pemigatinib and futibatinib are FDA approved FGFR-targeted therapies that have demonstrated remarkable responses. However, there is still a significant proportion of patients whose disease remains intrinsically resistant to treatment and most patients eventually develop secondary resistance after an initial response. Additionally, unique side effects of FGFR inhibitors may limit their efficacy in clinical practice and can have detrimental effects on quality of life. Several novel FGFR inhibitors are currently being investigated to overcome resistance mechanisms and reduce toxicities.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1245-1255"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new?

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-12 DOI: 10.1080/13543784.2024.2439501

Xinyuan Ning, Kashif M Munir, Stephen N Davis

{"title":"Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new?","authors":"Xinyuan Ning, Kashif M Munir, Stephen N Davis","doi":"10.1080/13543784.2024.2439501","DOIUrl":"10.1080/13543784.2024.2439501","url":null,"abstract":"Introduction: Type 1 diabetes is a chronic autoimmune condition characterized by the selective destruction of insulin-producing beta cells in the pancreas. The etiology of T1D is multifactorial, with a combination of genetic susceptibility and environmental triggers believed to underlie beta-cell destruction. Preserving and prolonging beta-cell function in T1D is a pivotal therapeutic objective that can mitigate disease progression and improve glycemic control.Areas covered: Insulin secretagogues have long been used in the management of type 2 diabetes, but do not have a significant beneficial effect in individuals with long-standing type 1 diabetes. Enhancement of beta-cell function early in the course of type 1 diabetes may offer important benefits in glycemic control and reduced hypoglycemia risk. Glucagon-like peptide-1 receptor agonists, glucokinase activators, free fatty acid receptor agonists, and glimins are drug classes which may offer benefit in enhancing insulin secretion in individuals with type 1 diabetes.Expert opinion: Drugs which enhance insulin secretion in individuals may offer clinical benefits to individuals with type 1 diabetes. However, the lack of beta-cell capacity introduces a challenge without regeneration of insulin-producing cells. Stem cell therapies combined with regulation of islet autoimmunity may offer the best prospect of increased insulin secretion in individuals with T1D.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1199-1208"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke. QHRD106作为一种安全有效的长效降凝血酶药物，可能有助于缺血性中风，这是首次进行人体研究。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/13543784.2024.2430200

Lei Huang, Runbin Sun, Hengwen Song, Zhiyou Chen, Yuxin Hong, Haoyi Yang, Yuwen Zhang, Lijun Wei, Fei Fei, Juan Li

{"title":"The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke.","authors":"Lei Huang, Runbin Sun, Hengwen Song, Zhiyou Chen, Yuxin Hong, Haoyi Yang, Yuwen Zhang, Lijun Wei, Fei Fei, Juan Li","doi":"10.1080/13543784.2024.2430200","DOIUrl":"10.1080/13543784.2024.2430200","url":null,"abstract":"Background: This study assessed the pharmacokinetics (PK), pharmacodynamics (PD) and safety of QHRD106, and made a comparison with urinary kallindinogenase (UKN) in healthy volunteers.Methods: This study comprised a randomized, double-blind, placebo-controlled, single-dose escalation phase and an open-label, multiple-dose escalation phase. Ninety-four subjects received intramuscular injections of QHRD106/placebo only once and 30 subjects received QHRD106 four times. Six subjects received 0.15 PNA units UKN intravenously for 7 d. PK and PD analysis were conducted by using a electrochemiluminescent assay and a liquid chromatography/mass spectrometry methodology, respectively. Cerebral circulation was assessed by the magnetic resonance imaging system.Results: QHRD106 exhibited a slow absorption profile in the human body. Compared to UKN, QHRD106-induced changes in bradykinin concentration later, but with a noticeably prolonged duration. Compared to baseline, cerebral blood flow exhibited a significant improvement on d 7 after a single dose of 18,900 IU and an improvement from d 2 to d 14 after multiple doses of 8400 IU of QHRD106. QHRD106 appeared generally good safety and no severe adverse events occurred in all the groups.Conclusions: This study provided initial evidence of potential treatment for ischemic strokes that the QHRD106 injection functioned as a safe and effective long-acting kallikrein drug.Registration: This study was registered on ClinicalTrials.gov with the identifier NCT06380699 and NCT06388772.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1257-1265"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigational drugs in early phase trials for myelofibrosis. 骨髓纤维化早期试验中的研究药物。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1080/13543784.2024.2434696

Sankalp Arora, Pankit Vachhani, Prithviraj Bose

{"title":"Investigational drugs in early phase trials for myelofibrosis.","authors":"Sankalp Arora, Pankit Vachhani, Prithviraj Bose","doi":"10.1080/13543784.2024.2434696","DOIUrl":"10.1080/13543784.2024.2434696","url":null,"abstract":"Introduction: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and organomegaly. Four JAK inhibitors are US-FDA approved for treatment of MF. While these drugs reduce symptom burden and spleen size to varying degrees, they do not affect the natural disease course or decrease the risk of leukemic transformation. Therefore, there is a strong need for newer therapies to further advance the field and improve the outcomes of MF. In this review, we cover novel therapies for MF currently in early stages of development.Areas covered: We present the latest data from early phase clinical trials in MF using drugs with diverse therapeutic mechanisms, including novel JAK-STAT pathway inhibitors, epigenetic therapies, antifibrotic agents, and immunotherapeutic strategies. Additionally, we cover drugs targeted toward anemia improvement in MF.Expert opinion: Numerous agents representing diverse drug classes are in clinical development for MF. While deeper and durable improvements in splenomegaly, symptoms, and anemia are the main clinical objectives, a number of putative biomarkers are being assessed as measures of potential 'disease modification.' Although JAK inhibitor monotherapy represents the current standard, it is hoped that JAK inhibitor-based rational combinations and driver mutation-specific therapies will soon usher in a new era.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1231-1244"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Hippo pathway as an antitumor target: time to focus on. 作为抗肿瘤靶点的 Hippo 通路：是时候关注了。

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1080/13543784.2024.2432395

Olga A Koroleva, Alexander V Kurkin, Alexander A Shtil

{"title":"The Hippo pathway as an antitumor target: time to focus on.","authors":"Olga A Koroleva, Alexander V Kurkin, Alexander A Shtil","doi":"10.1080/13543784.2024.2432395","DOIUrl":"10.1080/13543784.2024.2432395","url":null,"abstract":"Introduction: The Hippo signaling governs the expression of genes critically important for cell proliferation and survival. The components of this pathway are considered antitumor drug targets. However, the design of Hippo inhibitors is a challenge given the complexity of the network and redundancy of its elements.Areas covered: We review the current state-of-the-art in the structure of the Hippo pathway, the microenvironment-induced extracellular cues, the strategies to design pharmacological instruments for inactivation of the Hippo signaling using small molecular weight modulators, as well as the results of initial clinical trials.Expert opinion: One special characteristic of the Hippo signaling is the adverse role of phosphorylation: opposite to classical kinase cascades that activate the transcription factors, the Hippo kinases retain their partners in a transcriptionally inactive state. Therefore, approaches for pharmacological or genetic inhibition of Hippo protein kinases are counterproductive. The developing alternatives such as disruption of protein-protein interactions or PROTAC techniques are straightforward for preventing the Hippo signaling in cancer therapy.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1177-1185"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure.

IF 4.9 2区医学

Expert opinion on investigational drugs Pub Date : 2024-12-01 Epub Date: 2024-12-13 DOI: 10.1080/13543784.2024.2438663

Ashwin Ajay, Priyanga Biju, Hanan Ajay, Rajiv Tripathi, Gregory Y H Lip, Rajiv Sankaranarayanan

{"title":"Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure.","authors":"Ashwin Ajay, Priyanga Biju, Hanan Ajay, Rajiv Tripathi, Gregory Y H Lip, Rajiv Sankaranarayanan","doi":"10.1080/13543784.2024.2438663","DOIUrl":"10.1080/13543784.2024.2438663","url":null,"abstract":"Introduction: Acute failure is a critical condition, encompassed by the sudden or progressive onset of symptoms or signs of congestion. The treatment strategies available are mainly supportive and do not improve mortality or long-term outcomes. Therefore, there is a need for alternative novel treatment strategies. In this narrative review, we explore the role of relaxin agonist as a potential therapeutic strategy in acute heart failure.Areas covered: We aim to provide an overview of the evidence of preclinical and clinical studies on relaxin as a treatment strategy for acute heart failure. Papers collected in this review are from original research and systematic reviews which have been filtered following Medline and Cochrane Library searches.Expert opinion: Relaxin has shown great potential in both preclinical and clinical studies due to its antifibrotic, anti-inflammatory, and vasodilatory effect on the heart. However, there has been mixed evidence from clinical trials involving relaxin which could be due to patient groups, investigation sites, trial design, and chance. Further studies should focus on developing biomarkers to identify specific population groups who are most likely to benefit from relaxin.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1209-1218"},"PeriodicalIF":4.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0